Online inquiry

IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11043MR)

This product GTTS-WQ11043MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ERBB2&ERBB3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001005862.3; NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064; 2065
UniProt ID P04626; P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11043MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11946MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ9037MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ6124MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA COR-001
GTTS-WQ9029MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ2930MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG888
GTTS-WQ6397MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CT-011
GTTS-WQ750MR IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AAB-001
GTTS-WQ282MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 177lu-DOTA-HH1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW